HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hunault, M. Search for Related Content PubMed PubMed Citation Articles by Hunault, M.

Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial

From the Haematology Departments of Angers (MH, MT-G, NI); Dijon (DC); Nantes (J-LH); Nancy (SB); Reims (CH); Saint Etienne (DG); Brest (CB); and Bobigny (PC); Cytogenetics Department of Angers (LB); Immunology Department of Nancy (M-CB); Haematology Department of Tours (EG) France

Correspondence: Emmanuel Gyan, Service d’hématologie, CHU de Tours Hôpital Bretonneau, 2 boulevard Tonnellé, 37044 Tours CEDEX., E-mail: e.gyan{at}chu-tours.fr

Background and Objectives: T-lymphoblastic lymphoma is an infrequent disease usually treated as T-acute lymphoblastic leukemia with an induction chemotherapy course and sequential reinduction and maintenance chemotherapy. The T-LBL/ALL-GOELAL02 study evaluated the impact of randomized reinduction chemotherapy against intensified conditioning followed by autologous stem cell transplantation (ASCT), after an induction regimen of the type used for acute lymphoblastic leukemia (ALL).

Design and Methods: Patients with favorable characteristics were randomized to receive chemotherapy or ASCT. Patients with unfavorable characteristics (bone marrow involvement and age over 35 years old or leukocytosis >30 x 10⁹/L or failure to achieve medullar complete remission [CR] after one induction course) received a second induction course and ASCT.

Results: Among 45 patients, the CR rate was 71% after induction and 87% after a second induction course. Within the group of 27 patients with favorable characteristics, ten received ASCT and 17 chemotherapy. Ten patients in the group with unfavorable characteristics received ASCT. The 7-year overall survival and progression-free survival rates were 64 and 65%, respectively. Surprisingly, CR obtained after only two induction courses was associated with improved overall survival (p=0.04). None of the known prognostic factors significantly affected survival.

Interpretation and Conclusions: Randomized maintenance or high-dose therapy (HDT) and ASCT or intensified HDT according to initial presentation gave similar overall and relapse-free survival rates. However, HDT allowed sparing of mediastinal irradiation and shortened treatment duration.

Key words: lymphoblastic lymphoma, autologous bone marrow transplantation, lymphoblastic acute leukemia.

This article has been cited by other articles:

				M. Hunault-Berger, P. Chevallier, M. Delain, C.-E. Bulabois, S. Bologna, M. Bernard, I. Lafon, J. Cornillon, A. Maakaroun, A. Tizon, et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study Haematologica, October 1, 2008; 93(10): 1488 - 1494. [Abstract] [Full Text] [PDF]